Drug Discovery
ByChina Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution or Data Control Play?
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
NVIDIA Survey: 70% US Healthcare AI Adoption—Efficiency Lifeline or Insider Breach Timebomb?
NVIDIA’s March 1 survey shows 70% of US healthcare organizations now use AI, mainly to save time on…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
